ArticleBMC infectious diseases2025
In silico design and validation of a Plasmodium falciparum multi-epitope diagnostic antigen (PfMEDA1) for the diagnosis of falciparum malaria.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite efforts to curb the debilitating effects of malaria, incidence is still on the rise. Rapid diagnosis and effective treatment remain key strategies for reducing morbidity and mortality. The limitations of common antigens used for rapid diagnosis necessitate the search for alternatives. Studies carried out by Azcárate and colleagues have identified immunogenic proteins expressed in both clinical and subclinical malaria, which can therefore serve as diagnostic targets. This study is aimed at designing and validating a multi-epitope antigen to detect Plasmodium falciparum.
methodsThe amino acid sequences of five proteins previously reported to be immunogenic in infected malaria cases were retrieved from the Uniprot database, and linear B-cell epitopes were predicted and joined using GSGSG linkers to produce a chimeric protein (PfMEDA1). The physicochemical properties of the protein, as well as the secondary and tertiary structures, were predicted. The gene sequence of the protein after reverse transcription and codon optimization was synthesized, cloned into a pET30a(+) vector, expressed, and purified from E coli. Antibody reactivity against PfMEDA1 was assessed using an indirect ELISA with human serum samples from infected (n = 223) and non-infected (n = 81) malaria cases collected from hospitals in Fako Division of the South West Region of Cameroon.
resultsThe in silico-designed protein was predicted to be soluble, stable in varying climatic conditions, and immunogenic. There was a significant difference (P < 0.0001) observed between the mean OD in infected and non-infected samples, with a diagnostic sensitivity of 89.69% (95 CI: 84.93 to 93.35), diagnostic specificity of 75.31(95% CI: 64.47 to 84.22) and a Cohen kappa value of 0.64 implying slight substantial agreement with the PCR serving as the reference method.
conclusionDespite limitations of sample size and the need for field validation in settings of varied endemicity to establish its true diagnostic potential, PfMEDA1, in the current study, has shown potential as a diagnostic antigen. CLINICAL TRIAL: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.